Altre lingue Inhibitor Therapeutics, Inc.

Azioni

INTI

US45720M1053

Mercato chiuso - OTC Markets Altri mercati azionari 16:39:25 20/06/2024			Variaz. 5gg	Var. 1 gen.
0,079 ^USD	-0,05%		0,00%	-14,13%

13/05	Inhibitor Therapeutics, Inc. riporta i risultati degli utili per il primo trimestre conclusosi il 31 marzo 2024	CI
29/03	Inhibitor Therapeutics, Inc. riporta i risultati degli utili per l'intero anno terminato il 31 dicembre 2023	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Inhibitor Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	13/05
Inhibitor Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/03
Introducing Inhibitor Therapeutics, Inc. New Scientific Advisory Board	20/12
Inhibitor Therapeutics, Inc. Announces the Use of Itraconazole to Treat Basal Cell Carcinoma Nevus Syndrome	19/12
Introducing Inhibitor Therapeutics, Inc. Announces Scientific Advisory Board	19/12
Inhibitor Therapeutics, Inc. Enters into an Exclusive, Worldwide Licensing Agreement with Johns Hopkins University	14/12
Inhibitor Therapeutics, Inc. Exclusive License with Johns Hopkins University	13/12
Inhibitor Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13/11
Inhibitor Therapeutics, Inc. Appoints Michelle Yanez as an Independent Director and a Member of the Audit Committee	18/10/23
Inhibitor Therapeutics, Inc. Appoints Ronald E. Osman as Non-Independent Director on the Board	29/08/23
Inhibitor Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11/08/23
INHIBITOR THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)	31/05/23
Inhibitor Therapeutics, Inc. Announces Board Changes	31/05/23
Inhibitor Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/05/23
INHIBITOR THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	31/03/23
Inhibitor Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	31/03/23
INHIBITOR THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Changes in Control or Registrant, Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)	19/12/22
INHIBITOR THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	14/11/22
Inhibitor Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	14/11/22
Inhibitor Therapeutics : NOTICE OF PENDENCY OF DERIVATIVE AND CLASS ACTIONS, PROPOSED SETTLEMENT AND SETTLEMENT HEARING - Form 8-K	15/09/22

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Inhibitor Therapeutics, Inc.

Azioni

INTI

US45720M1053

Altre lingue

Filtri